We are proud to share new research led by our Scientific Advisory Board Chair, Dr. Andreana Holowatyj, and published in the Annals of Internal Medicine, finding that appendix cancer rates have quadrupled among Millennials. This landmark study, funded in part by The Appendix Cancer Research Foundation and the National Institutes of Health, was featured in The New York Times, TIME...

Patient Power recently invited cancer patients to share their individual thoughts, feelings, and experiences from diagnosis and beyond. The responses were then reported in the article below. They are all insightful and highlight the many challenges. Notably, the patient community as a whole reported many of the same perceptions and experiences. The responses are provided below. As we often say,...

Explore Our Refreshed and Expanded Clinical Trials Database ACPMP is excited to announce a significant update to our Clinical Trials Database – an important resource for physicians and their patients seeking clinical trials for appendix cancer. This update is part of our larger effort to provide the appendix cancer community with the most current and comprehensive information available. Here are...

The Appendix Cancer PMP Research Foundation (ACPMP) proudly announces the publication of a landmark article in Nature Reviews Cancer entitled “Defining a 'cells to society' research framework for appendiceal tumors.” This pivotal Expert Recommendation, officially published online on February 20, is the direct result of the Appendix Cancer PMP Research Foundation Scientific Think Tank—an innovative, multidisciplinary gathering designed to advance...

Thanks to the generosity of our donors, ACPMP is proud to fund two 2025 Society of Surgical Oncology (SSO) research grants focused solely on appendix cancer and PMP—including a significant new award in memory of our founder. SSO advances cancer research by providing research funding through its competitive Clinical Investigator and Young Investigator Awards programs. Introducing the Lisa Kurtz Luciano Appendix Cancer and Pseudomyxoma...

February is recognized as National Cancer Prevention Month, an important time to discuss ways to reduce cancer risks and promote overall health. Yet, for appendix cancer—including Pseudomyxoma Peritonei (PMP)—no specific causes have been definitively identified. Below, we’ll explore what is currently known about appendix cancer, share general cancer prevention strategies recommended by leading authorities, and highlight the importance of ongoing...

$50,000 Grant Awarded to Dr. Andrew Lowy for Groundbreaking Research on Mucinous Appendix Cancer SPRINGFIELD, PA, UNITED STATES, December 19, 2024 /EINPresswire.com/ -- The Appendix Cancer PMP Research Foundation (ACPMP) is pleased to announce a historic achievement: the launch of a second Catalyst Research Grant cycle within the same year, culminating in the funding of a third $50,000 research grant in 2024....

Giving Tuesday, celebrated annually on the Tuesday after Thanksgiving, is a global day of giving fueled by the power of collaboration and community. It’s a day when people come together to support causes close to their hearts and make a tangible impact. This year, the Appendix Cancer PMP Research Foundation joined the movement once again, and thanks to your generosity,...

SPRINGFIELD, PA, UNITED STATES, October 17, 2024 / -- The 2024 Annual Virtual Appendix Cancer Multi-Regional Symposium, presented by the Appendix Cancer Pseudomyxoma Peritonei Research Foundation (ACPMP), will be held on November 1, 2024. Co-sponsored by leading medical institutions including Yale Cancer Center, Atrium Health Levine Cancer, and University of Utah Huntsman Cancer Institute, this symposium will bring together top scientists,...

Researchers at UC San Diego have found that palbociclib, a breast cancer drug, shows promise for treating a rare form of appendix cancer called peritoneal mucinous carcinomatosis (PMC). Dr. Andrew Lowy, co-senior author and ACPMP Medical Advisory Board Member, says, "Finding that a breast cancer drug is successful in treating a subset of appendix cancer — where treatment options are...